Matt Kohlmann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Matt Kohlmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Matt Kohlmann Today - Breaking & Trending Today

Semaglutide 2.4 mg (Wegovy) Reduces Cardiovascular Risk in Overweight/Obesity with CVD

Published: November 11, 2023

Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.

Source: hcplive.com

Related Topics:

United StatesTiffanym PowellAmit KheraCampbellp Semaglutide WegovyMatt KohlmannPa Michael LincoffAmerican Heart AssociationNovo NordiskNational Institutes Of HealthSuzanne Tomsich Department Of Cardiovascular MedicineUniversity Of Texas Southwestern Medical CenterVascular Thoracic InstituteAmerican Heart Association Scientific SessionsCleveland ClinicSuzanne Tomsich DepartmentCardiovascular MedicineArnold Miller Family HeartThoracic InstituteStandard DeviationTexas Southwestern Medical CenterNational InstitutesCardiovascular OutcomesNew England JournalAccessed NovemberCardiovascular Disease